Macrophage migration inhibitory factor (MIF) has been implicated in mediating both innate and adaptive immune responses in inflammatory and infectious diseases. The sequence and structure of MIF is highly conserved across the avian phylogeny, which underlies high sequence homology and functional similarities between turkey and chicken MIFs. Turkey MIF (TkMIF) inhibited cell migration and promoted cell proliferation with production of inflammatory mediators, comparable to the biological properties of chicken MIF (ChMIF), thus indicating the biological cross-reactivity between turkey and chicken MIFs. This study identified the cell surface receptor(s) that could bind ChMIF and the biological roles triggered by such interactions. In addition to CD74, a previously identified receptor, CXCR4 also interacts with ChMIF. Moreover, the formation of receptor complexes was shown between CXCR4 and CD74. MIF signaling through CXCR4 and CD74 led to cell chemotaxis and proliferation activity as well as intracellular calcium influx. Intriguingly, Eimeria MIF (EMIF), a homologue secreted following parasitic infection, also interacted with CD74 leading to comparable biological functions to those of ChMIF. Given such observations, we hypothesized that CXCR4 and CD74 are receptors for ChMIF leading to the functional consequences similarly manifested by EMIF interaction with the corresponding receptors. EMIF, predominantly secreted from the invasive merozoite stage, may help the parasite exploit the host immune response by interacting with common ChMIF receptors. This may lead to functional mimicry thus provoking the question of whether EMIF would modulate the biological functions of ChMIF to manipulate the host defense that allows more efficient invasion of the host. To evaluate this concept, a transgenic E. tenella lacking MIF was generated by in vivo passage of E. tenella transfected with a CRISPR plasmid targeting EMIF. Although not fully disrupted, reduction of EMIF expression was observed in the transgenic E. tenella itself as well as in inoculated cells, which resulted in enhanced survival of host cells. Herein, we achieved a better characterization of the functional roles of both avian and parasite MIFs underlying the interaction with common host receptors, along with the essential role of parasite MIF promoting host cell death during parasitic infection. / PHD / When animals get infected or injured, their immune system senses invading pathogens or damaged tissues as danger signals, which often elicits the production of inflammatory mediators. These are chemical messengers secreted mostly by immune cells that initiate cellular communication and infiltration of immune cells to the infection/damaged site leading to inflammatory responses to eliminate the infectious agents and repair damaged tissues. Among many inflammatory mediators, macrophage migration inhibitory factor (MIF) is involved in inflammatory and immune response by regulating cell migration. Interestingly, MIF is secreted by Eimeria parasites (that cause the costly coccidiosis disease in poultry) as well as by chickens (host animal) after infection with this pathogen. Toward a better understanding of the impacts of both avian and parasite MIFs on the host immune response, three specific studies were completed. First, MIF displayed high degree of gene sequence identity and functional similarity between chicken and turkey, supporting the evolutionarily conservation of MIF across birds. The second study identified the MIF receptors and their complexes, which engage in the biological functions of chicken MIF. Through binding to these cell surface receptors, chicken MIF can regulate cell migration and proliferation with calcium release. Intriguingly, Eimeria MIF secreted after parasitic infection is able to bind the same receptors leading to comparable biological functions to those of chicken MIF. Lastly, the role of Eimeria MIF was further evaluated by disrupting its gene in the parasite. Although not fully disrupted in the transgenic parasites, its expression was decreased resulting in enhanced survival of host cells, thus suggesting a deleterious effect of Eimeria MIF on the host, as well as its potential as a therapeutic target to control coccidiosis in poultry.

Thesis advisor: Jia Niu / In the last ten years, programmable CRISPR-Cas systems have been widely-used as genome editing tools for gene manipulation, epigenetic functionalization, and transcriptional regulation. Among them, fusing effector proteins directly to the Cas protein allows the resulting CRISPR machinery to direct these effector proteins to multiple sites of the same gene or multiple genes at once. Although they can be used to target multiple genetic loci simultaneously, these methods are often limited to applying one regulatory function (e.g., activation or repression) at a time. On the other hand, recruiting effector proteins via RNA aptamer-RNA-binding protein (RBP) recognition enabled multiplexed and multi-modular gene manipulations simultaneously. However, there are only a limited set of aptamer-RBP pairs that can function orthogonally and intracellularly, e.g., MS2 RNA aptamer with MS2 coat protein (MCP), and PP7 RNA aptamer with PP7 coat protein (PCP). The scarcity of orthogonal intracellular aptamer-RBP pairs imposes severe constraints on the CRISPR-mediated multifunctional manipulations of the genome and the epigenome. We established an intracellular selection platform for RNA aptamers, named CRISPR-Hybrid, and expanded the scope of aptamer-RBP toolkit for CRISPR transcription regulators. Using CRISPR-Hybrid, we successfully identified a highly active and specific aptamer for bacteriophage Qβ coat protein (QCP) in vivo, and characterized its binding affinity and specificity in vitro. We further validated the orthogonality of selected aptamer with QCP to other available intracellularly functional aptamer-RBP pairs including MS2-MCP and PP7-PCP in mammalian cells. Finally, we demonstrated the utility of this orthogonal pair in multiplexed and multi-modular regulations of endogenous genes. / Thesis (PhD) — Boston College, 2024. / Submitted to: Boston College. Graduate School of Arts and Sciences. / Discipline: Chemistry.

La maladie de Huntington (MH) est une maladie neurodégénérative caractérisée par plusieurs symptômes moteurs, cognitifs et psychiatriques, causés par une expansion du trinucléotide CAG présent dans le gène huntingtine. L’expression de la protéine correspondante mène éventuellement à un dysfonctionnement et une mort cellulaire. OBJECTIFS: À ce jour, il n’existe pas de thérapies efficaces afin de traiter ou ralentir la MH, mais les essais actuels suggèrent qu’une réduction de la quantité de protéines mutantes pourrait être bénéfique. Dans cette étude, il a été question d’utiliser le système CRISPR/Cas9. Grâce à l’utilisation de l’enzyme Cas9, cette technologie d’édition du génome bien précise permet de cibler et corriger une mutation génétique; ce qui permettrait dans le cas de la MH de réduire le gène causant la pathologie. MÉTHODE : Un modèle de souris MH et un modèle contrôle sauvage, âgés de 12 mois, ont reçu des injections stéréotaxiques intracérébrales de virus AAV9 contenant la Cas9D10A et/ou l’ARN guide (SgCTG/eGFP). Des tests cognitifs et moteurs ont été effectués pendant 3 mois après les injections virales. Des tissus et du sang ont été récoltés lors du sacrifice des animaux. Les échantillons de cerveaux ont été analysés par immunofluorescence et par western blot pour déterminer le degré de contraction ainsi que le niveau d’expression et de colocalisation de la Cas9D10A et de l’ARN guide. RÉSULTATS: Une amélioration de certains comportements est notable après 3 mois post-injection chez les souris MH traitées avec les deux constructions. Les analyses biochimiques ont permis de détecter l’expression des deux vecteurs et une réduction de la quantité de protéines mutées. CONCLUSION : CRISPR/Cas9 pourrait potentiellement être utilisé pour réduire la quantité de protéines mutées et améliorer certains comportements cognitifs et moteurs. Une optimisation de l’utilisation de cette technologie pourrait mener à une thérapie intéressante pour la MH / Huntington’s disease (HD) is a neurodegenerative disorder characterized by a triad of motor, cognitive and psychiatric symptoms which results from an expansion of the CAG tract in the huntingtin gene. This mutation encodes for a longer polyglutamine stretch in the mutant huntingtin protein. Expression of the mutant protein eventually leads to cell dysfunction and death. OBJECTIVE: To this day, there is no disease-modifying therapy available for HD, but ongoing trials suggest that reducing the amount of the mutant protein could be beneficial. In this study we used the CRISPR/Cas9 system, a precise gene editing technology which can be directly employed with its partner enzyme, Cas9, to specifically target and correct genetic mutations, to shrink the causative mutation associated with HD. METHODS: A mice model of HD and littermate controls were aged to 12 months prior to undergoing stereotaxic intracerebral injections of AAV9 viruses containing either Cas9 D10A nickase and/or guide RNA (SgCTG/eGFP) targeted to the CAG expansion. Cognitive and motor testing were performed for 3 months after viral infection. Tissues and blood were collected at the completion of the protocol. Brain samples were analysed using immunofluorescence and western blotting to determine the degree of contraction achieved and the degree of expression and colocalization of GFP (guide RNA) and HA tags (Cas9D10A). RESULTS: Mild behavioural improvements were detected 3 months after co-administration of the two viral constructs to HD mice. Importantly, biochemical studies detected expression of both the guide RNA and the Cas9 in addition to a reduction in the amount of mHTT detected in HD mice receiving both viruses. CONCLUSION: CRISPR/Cas9 can be used to reduce the amount of mHTT and this is associated with improvements in cognitive and fine motor deficits. Further optimization of this technology could lead to a clinically relevant therapy.

Cystic fibrosis is an autosomal recessive disease caused by mutations in the CFTR gene. A significant number of mutations (~13%) alter the correct splicing of the CFTR gene, causing the transcription of aberrant transcripts resulting in the production of a non-functional CFTR channel. We focus our research on two intronic CF causing mutations, 3272-26A>G and 3849+10kbC>T that create a new acceptor and donor splice site, respectively, generating in the inclusion of intronic portions into the mRNA. We developed a new genome editing approach to permanently correct the abovementioned mutations by means of CRISPR nucleases. We exploited the use of either Streptococcus pyogenes Cas9, SpCas9, or Acidaminococcus sp. BV3L6, AsCas12a, to edit the aberrant splicing sites and restore the production of the correct transcript, avoiding modifications of the CFTR coding sequence. A comparative analysis between SpCas9 and AsCas12a revealed that the use of AsCas12a with a single crRNA efficiently edits the target loci, producing correctly spliced mRNAs in both 3272-26A>G and 3849+10kbC>T mutations. Furthermore, this genetic repair strategy proved to be highly specific, exhibiting a strong discrimination between the mutated and the wild-type allele and no detectable off-target activity with genome-wide analysis. The selected crRNAs were tested in patients derived primary airway cells and intestinal organoids compound heterozygous for the 3272-26A>G or 3849+10kbC>T mutations, that are considered relevant CF models for translational research. The efficient splicing repair and the complete recovery of CFTR channel activity observed confirmed the goodness of the proposed gene editing strategy. These results demonstrated that allele-specific genome editing with AsCas12a can correct aberrant CFTR splicing mutations, paving the way for a permanent splicing correction in genetic diseases.

The evolutionary success of higher plants is largely attributed to their tremendous developmental plasticity, which allows them to cope with adverse conditions. However, because these adaptations require investments of resources, they must be tightly regulated to avoid unfavourable trade-offs. Most of the resources required are macronutrients based on carbon and nitrogen. Limitations in the availability of these nutrients have major effects on gene expression, metabolism, and overall plant morphology. These changes are largely mediated by the highly conserved master kinase SNF1-RELATED PROTEIN KINASE1 (SnRK1), which represses growth and induces catabolic processes. Downstream of SnRK1, a hub of heterodimerising group C and S1 BASIC LEUCINE ZIPPER (bZIP) transcription factors has been identified. These bZIPs act as regulators of nutrient homeostasis and are highly expressed in strong sink tissues, such as flowers or the meristems that initiate lateral growth of both shoots and roots. However, their potential involvement in controlling developmental responses through their impact on resource allocation and usage has been largely neglected so far. Therefore, the objective of this work was to elucidate the impact of particularly S1 bZIPs on gene expression, metabolism, and plant development. Due to the high homology and suspected partial redundancy of S1 bZIPs, higher order loss-of-function mutants were generated using CRISPR-Cas9. The triple mutant bzip2/11/44 showed a variety of robust morphological changes but maintained an overall growth comparable to wildtype plants. In detail however, seedlings exhibited a strong reduction in primary root length. In addition, floral transition was delayed, and siliques and seeds were smaller, indicating a reduced supply of resources to the shoot and root apices. However, lateral root density and axillary shoot branching were increased, suggesting an increased ratio of lateral to apical growth in the mutant. The full group S1 knockout bzip1/2/11/44/53 showed similar phenotypes, albeit far more pronounced and accompanied by growth retardation. Metabolomic approaches revealed that these architectural changes were accompanied by reduced sugar levels in distal sink tissues such as flowers and roots. Sugar levels were also diminished in leaf apoplasts, indicating that long distance transport of sugars by apoplastic phloem loading was impaired in the mutants. In contrast, an increased sugar supply to the proximal axillary buds and elevated starch levels in the leaves were measured. In addition, free amino acid levels were increased in bzip2/11/44 and bzip1/2/11/44/53, especially for the important transport forms asparagine and glutamine. The increased C and N availability in the proximal tissues could be the cause of the increased axillary branching in the mutants. To identify bZIP target genes that might cause the observed shifts in metabolic status, RNAseq experiments were performed. Strikingly, clade III SUGARS WILL EVENTUALLY BE EXPORTED (SWEET) 8 genes were abundant among the differentially expressed genes. As SWEETs are crucial for sugar export to the apoplast and long-distance transport through the phloem, their reduced expression is likely to be the cause of the observed changes in sugar allocation. Similarly, the reduced expression of GLUTAMINE AMIDOTRANSFERASE 1_2.1 (GAT1_2.1), which exhibits glutaminase activity, could be an explanation for the abundance of glutamine in the mutants. Additional experiments (ATAC-seq, DAP� seq, PTA, q-RT-PCR) supported the direct induction of SWEETs and GAT1_2.1 by S1 bZIPs. To confirm the involvement of these target genes in the observed S1 bZIP mutant phenotypes, loss-of-function mutants were obtained, which showed moderately increased axillary branching. At the same time, the induced overexpression of bZIP11 in axillary meristems had the opposite effect. Collectively, a model is proposed for the function of S1 bZIPs in regulating sink tissue development. For efficient long-distance sugar transport, bZIPs may be required to induce the expression of clade III SWEETs. Thus, reduced SWEET expression in the S1 bZIP mutants would lead to a decrease in apoplastic sugar loading and a reduced supply to distal sinks such as shoot or root apices. The reduction in long� distance transport could lead to sugar accumulation in the leaves, which would then increasingly be transported via symplastic routes towards proximal sinks such as axillary branches and lateral roots or sequestered as starch. The reduced GAT1_2.1 levels lead to an abundance of glutamine, a major nitrogen transport form. The combined effect on C and N allocation results in increased nutrient availability in proximal tissues, promoting the formation of lateral plant organs. Alongside emerging evidence highlighting the power of bZIPs to steer nutrient allocation in other species, a novel but evolutionary conserved role for S1 bZIPs as regulators of developmental plasticity is proposed, while the generation of valuable data sets and novel genetic resources will help to gain a deeper understanding of the molecular mechanisms involved / Der evolutionäre Erfolg höherer Pflanzen wird weitgehend auf ihre enorme Entwicklungsplastizität zurückgeführt, die es ihnen ermöglicht, widrigen Bedingungen zu trotzen. Da diese Anpassungen jedoch einen immensen Ressourceneinsatz erfordern, müssen sie streng reguliert werden, um unvorteilhafte Reaktionen zu vermeiden. Den Großteil der benötigten Ressourcen machen Makronährstoffe auf der Basis von Kohlenstoff und Stickstoff aus. Eine eingeschränkte Verfügbarkeit dieser Nährstoffe hat erhebliche Auswirkungen auf die Genexpression, den Stoffwechsel und die Morphologie der Pflanzen. Diese Veränderungen werden größtenteils durch die hochkonservierte Kinase SNF1-RELATED PROTEIN KINASE1 (SnRK1) vermittelt, die das Wachstum unterdrückt und katabole Prozesse einleitet. Downstream von SnRK1 wurde ein Netzwerk von heterodimerisierenden Transkriptionsfaktoren der Gruppe C und S1 BASIC LEUCINE ZIPPER (bZIP) identifiziert. Diese bZIPs wirken als Regulatoren der Nährstoffhomöostase und werden vor allem in starken sink-Geweben wie Blüten oder den Meristemen, die das Seitenwachstum von Sprossen und Wurzeln ermöglichen, exprimiert. Ihre potenzielle Beteiligung an der Steuerung von Entwicklungsreaktionen durch ihren Einfluss auf die Ressourcenzuteilung und -nutzung wurde bisher jedoch weitgehend vernachlässigt. Ziel dieser Arbeit war es daher, die Auswirkungen insbesondere von S1 bZIPs auf die Genexpression, den Stoffwechsel und die Pflanzenentwicklung zu erforschen. Aufgrund der hohen Homologie und der vermuteten teilweisen Redundanz der S1 bZIPs wurden mithilfe von CRISPR-Cas9 loss-of-function Mutanten höherer Ordnung erzeugt. Die Dreifachmutante bzip2/11/44 zeigte eine Vielzahl robuster morphologischer Veränderungen, behielt aber insgesamt ein mit Wildtyp-Pflanzen vergleichbares Wachstum bei. Im Detail jedoch wiesen die Keimlinge eine starke Verringerung der Primärwurzellänge auf. Darüber hinaus verzögerte sich der Blühzeitpunkt, und die Schoten und Samen waren kleiner, was auf eine geringere Versorgung der Spross- und Wurzelspitzen mit Ressourcen hinweist. Die Dichte der Seitenwurzeln und die axilläre Verzweigung des Sprosses waren jedoch erhöht, was auf ein erhöhtes Verhältnis von lateralem zu apikalem Wachstum in der Mutante hindeutet. Die Knockout-Mutante bzip1/2/11/44/53 zeigte ähnliche Phänotypen, wenn auch weitaus ausgeprägter und begleitet von Wachstumsverzögerungen. Metabolische Untersuchungen ergaben, dass diese Veränderungen in der Architektur mit reduzierten Zuckerspiegeln in distalen sink� Geweben wie Blüten und Wurzeln einhergingen. Die Zuckerspiegel waren auch in den Apoplasten der Blätter vermindert, was darauf hindeutet, dass der Ferntransport von Zucker durch apoplastische Phloembeladung in den Mutanten beeinträchtigt war. Im Gegensatz dazu wurden eine erhöhte Zuckerzufuhr zu den proximalen Achselknospen und erhöhte Stärkekonzentrationen in den Blättern gemessen. Zusätzlich war die Konzentration freier Aminosäuren in bzip2/11/44 und bzip1/2/11/44/53 10 erhöht, insbesondere für die wichtigen Transportformen Asparagin und Glutamin. Die erhöhte C- und N-Verfügbarkeit in den proximalen Geweben könnte die Ursache für die verstärkte axilläre Verzweigung in den Mutanten sein. Um bZIP-Zielgene zu identifizieren, die die beobachteten Verschiebungen im Stoffwechselstatus verursachen könnten, wurden RNAseq-Experimente durchgeführt. Auffallend ist, dass die Gene der Gruppe III SUGARS WILL EVENTUALLY BE EXPORTED (SWEET) unter den unterschiedlich exprimierten Genen sehr häufig vorkamen. Da SWEETs für den Zuckerexport in den Apoplasten und den Langstreckentransport durch das Phloem von entscheidender Bedeutung sind, ist ihre verringerte Expression wahrscheinlich die Ursache für die beobachteten Veränderungen in der Zuckerallokation. Ebenso könnte die verringerte Expression von GLUTAMIN AMIDOTRANSFERASE 1_2.1 (GAT1_2.1), die Glutaminase-Aktivität aufweist, eine Erklärung für die Häufigkeit von Glutamin in den Mutanten sein. Zusätzliche Experimente (ATAC-seq, DAP-seq, PTA, q-RT-PCR) bestätigten die direkte Induktion von SWEETs und GAT1_2.1 durch S1 bZIPs. Um die Beteiligung dieser Zielgene an den in den S1 bZIP� Mutanten beobachteten Phänotypen zu bestätigen, wurden loss-of-function-Mutanten untersucht, die eine mäßig erhöhte axilläre Verzweigung aufwiesen. Gleichzeitig hatte die induzierte Überexpression von bZIP11 in axillären Meristemen den gegenteiligen Effekt. Auf Basis dieser Ergebnisse wird ein Modell für die Funktion von S1 bZIPs bei der Regulierung der Entwicklung von sink-Geweben vorgeschlagen. Für einen effizienten Zuckertransport über große Entfernungen könnten bZIPs erforderlich sein, um die Expression von SWEETs der Gruppe III zu induzieren. Eine verringerte SWEET-Expression in den S1 bZIP-Mutanten würde zu einem Rückgang der apoplastischen Zuckerbeladung und einer verringerten Versorgung von distalen sink-Geweben wie den Spross- oder Wurzelspitzen führen. Die Verringerung des Ferntransports könnte zu einer Anhäufung von Zucker in den Blättern führen, der dann verstärkt über symplastische Wege zu proximalen sink� Geweben wie den axillären Meristem und Seitenwurzeln transportiert oder als Stärke gespeichert wird. Die verringerte GAT1_2.1 Expression führt zu einem Überfluss an Glutamin, einer wichtigen Stickstofftransportform. Die kombinierte Wirkung auf die C- und N-Allokation führt zu einer erhöhten Nährstoffverfügbarkeit in den proximalen Geweben und fördert die Bildung von seitlichen Pflanzenorganen. Neben neuen Erkenntnissen, die die Wirksamkeit von bZIPs bei der Steuerung der Nährstoffallokation in anderen Arten unterstreichen, wird eine neuartige, jedoch evolutionär konservierte Rolle für S1 bZIPs als Regulatoren der Entwicklungsplastizität vorgeschlagen, während die Generierung wertvoller Datensätze und neuer genetischer Ressourcen dazu beitragen wird, ein tieferes Verständnis der beteiligten molekularen Mechanismen zu gewinnen.

As integrinas constituem uma família de receptores de membrana que tem como função primária a adesão de células a proteínas da matriz extracelular e alguns de seus membros estão envolvidos nos processos de diferenciação osteoblástica e formação óssea, eventos diretamente relacionados à osseointegração de implantes de titânio (Ti). Sabe-se que superfícies de Ti com nano e microtopografia podem favorecer a diferenciação osteoblástica e a mineralização da matriz extracelular. No entanto, os mecanismos celulares envolvidos nesses processos não são completamente entendidos. Neste contexto, os objetivos deste estudo foram: (1) caracterizar as superfícies de Ti com nano (Ti-Nano) e microtopografia (Ti-Micro), (2) investigar a participação da integrina V na diferenciação osteoblástica induzida pelo Ti-Nano e (3) investigar a participação da integrina β3 na diferenciação osteoblástica induzida por Ti-Nano e Ti-Micro. Para isso, discos de Ti-Nano e Ti-Micro foram preparados por ataque ácido com H2SO4/H2O2 ou com HNO3/H2SO4 / HCl, respectivamente, e caracterizados quanto à topografia, rugosidade e composição química de superfície. Discos de Ti usinados foram usados com controle (Ti-Controle) em alguns experimentos. Células-tronco mesenquimais derivadas de medula óssea de ratos foram cultivadas sobre as três superfícies de Ti e foi avaliada a expressão gênica de componentes envolvidos na via de sinalização das integrinas por PCR array. Com base nos resultados do PCR array, as integrinas αV e β3 foram selecionadas e silenciadas por RNA de interferência (shRNA) ou CRISPR/Cas9, respectivamente, em células pré-osteoblásticas da linhagem MC3T3-E1 para investigarmos a participação dessas integrinas na diferenciação osteoblástica induzida por superfícies de Ti com diferentes topografias. Os resultados deste estudo mostraram que os tratamentos empregados foram eficientes para a produção de superfícies de Ti com topografias nas escalas nano e micrométrica. Além disso, foi demonstrado que o maior potencial osteogênico do Ti-Nano se deve, ao menos em parte, à integrina αV, uma vez que seu silenciamento reduziu a diferenciação osteoblástica induzida pela nanotopografia. Por fim, também demonstramos que a via de sinalização ativada pela integrina β3 exerce um papel fundamental no potencial osteogênico do Ti-Nano, mas não do Ti-Micro. O silenciamento da integrina β3 reduziu a diferenciação osteoblástica, concomitantemente com a regulação negativa da expressão de vários componentes das vias de sinalização de Wnt e de BMP, apenas nas células crescidas sobre a nanotopografia. Em conjunto, nossos resultados revelam um novo mecanismo para explicar a maior diferenciação osteoblástica induzida pelo Ti-Nano, que envolve uma complexa rede regulatória ativada pela maior expressão das integrinas αV e β3, esta última gerando ativação da transdução de sinal das vias de Wnt e de BMP / Integrins are a family of membrane receptors that primarily mediate cell adhesion to extracellular matrix proteins and some members are involved in the process of osteoblast differentiation and bone formation, key events of titanium (Ti) implant osseointegration. It is well known that Ti surfaces with nano and microtopography may favor osteoblast differentiation and matrix mineralization. However, the cellular mechanisms involved in this process are not entirely understood. In this context, the aims of this study were: (1) to characterize the Ti surfaces with nano (Ti-Nano) and microtopography (Ti-Micro), (2) to investigate the participation of integrin V on osteoblast differentiation induced by Ti-Nano and (3) to investigate the participation of integrin β3 on osteoblast differentiation induced by Ti-Nano and Ti-Micro. Discs of Ti-Nano and Ti-Micro were prepared with acid etching with H2SO4/H2O2 or with HNO3/H2SO4 / HCl, respectively, and characterized in terms of surface topography, roughness and chemical composition. Machined Ti discs (untreated) were used as control (Ti-Control) in some experiments. Mesenchymal stem cells from rat bone marrow were cultured on Ti discs with the three different surfaces and the gene expression of members of the integrin signaling pathway was evaluated by PCR array. Based on PCR array results, the integrins αV and β3 were selected and silenced using RNA interference (shRNA) or CRISPR-Cas9, respectively, in pre-osteoblastic cell line MC3T3-E1 to investigate the participation of these integrins in osteoblast differentiation induced by Ti with different surface topographies. The results showed that the treatments used were efficient to generate Ti surfaces with topographies at the nano and micrometric scales. We showed that the higher osteogenic potential of Ti-Nano may be, at least in part, due to the integrin &alphaV, since its silencing reduced the osteoblast differentiation induced by nanotopography. We also demonstrated that the signaling pathway triggered by integrin β3 plays a key role in the osteogenic potential of Ti-Nano, but not of Ti-Micro. The silencing of integrin β3 reduced the osteoblast differentiation concomitantly with the negative regulation of the gene expression of several Wnt and BMP signaling components only in cells grown on Ti-Nano. Taken together, our results uncover a novel mechanism to explain the higher osteoblast differentiation induced by Ti-Nano that involves a complex regulatory network triggered by integrins αV and β3 upregulation, with the integrin β3 activating the Wnt and BMP signal transductions

Mycoplasma hominis est un pathogène humain opportuniste responsable d’infections génitales et néo-natales. Modifier génétiquement cette bactérie est nécessaire afin de comprendre les mécanismes de virulence et d’infection de ce pathogène. Il n’existe à ce jour aucun outil moléculaire efficace permettant de manipuler le génome de M. hominis, limitant les recherches sur sa pathogénicité et son métabolisme particulier reposant sur l’arginine. De nouvelles technologies rassemblées sous le terme de Biologie de Synthèse (BS) ont récemment émergé, offrant des perspectives inédites pour l’étude des mycoplasmes en permettant de modifier leurs génomes à grande échelle et de produire des souches mutantes. Ces travaux menés au J. Craig Venter Institute (JCVI, USA) ont montré que le génome de mycoplasmes apparentés pouvait être cloné et manipulé dans la levure avant d’être transplanté dans une cellule receveuse. La levure sert d’hôte d’accueil temporaire pour modifier le génome de la bactérie. Cette approche novatrice ouvre de nombreuses perspectives dans le cadre du développement de la génomique fonctionnelle chez les mycoplasmes pour lesquels les outils génétiques efficaces sont peu nombreux. Le but de cette thèse a été d’adapter pour la première fois certains outils de BS à M. hominis dans le but de créer des mutants déficients pour une fonction donnée. Pour cela, le génome de la souche type de M. hominis PG21 (665 kb) a été cloné dans la levure Saccharomyces cerevisiae par « Transformation-Associated Recombination cloning » (TAR-cloning). Deux clones (B3-2 et B3-4) de levure possédant le génome complet de M. hominis ont été validés par analyse en PCR simplex, PCR multiplex et électrophorèse en champs pulsé (PFGE). Ces clones levures ont ensuite été propagés en milieu sélectif durant 180 générations (30 passages), afin d’évaluer la stabilité du génome bactérien dans son hôte. Cette expérience a montré que (i) si la taille du génome de M. hominis ne variait pas au cours des premiers passages, elle diminuait progressivement à partir du dixième passage (≈60 générations), et que (ii) les zones du génome enrichies en séquence répétées étaient préférentiellement perdues. En tenant compte de ces résultats, le génome de M. hominis a été modifié chez le clone B3-4 par la technique « Clustered Regularly Interspaced Short Palindromic Repeats/Cas9 » (CRISPR/Cas9) lors de passages précoces. Des clones de S. cerevisiae possédant un génome de M. hominis PG21 complet délété du gène vaa, codant une protéine d’adhésion majeure, ont été ainsi produits. La dernière étape de cette approche consistait à transplanter le génome modifié dans une cellule receveuse de M. hominis ou de Mycoplasma arthritidis, espèce phylogénétiquement la plus proche de M. hominis. Aucun protocole de transformation de M. hominis n’étant disponible au début de nos travaux, cette étape constituait un verrou majeur dans la mise en place des outils de BS chez cette espèce. Ce verrou a été en partie levé puisqu’une méthode de transformation de M. hominis basée sur du polyéthylène glycol (PEG) et mettant en jeu le plasposon pMT85 (plasmide contenant un transposon conférant la résistance à la tétracycline) a été mise au point au laboratoire. Cette technique de transformation, développée pour la souche de référence M. hominis M132 (745 kb) reste encore peu efficace ; elle est néanmoins reproductible et a permis d’obtenir des mutants d’intérêt de M. hominis. Le transformant n°28-2 a, ainsi, été muté dans le gène Mhom132_2390, codant le précurseur de la protéine P75, une adhésine putative de M. hominis. Le séquençage des génomes complets d’autres transformants a révélé l’insertion de multiples copies du transposon et la présence d’évènements de duplication et d’inversion de larges fragments d’ADN dans au moins deux génomes de M. hominis. / Mycoplasma hominis is an opportunistic human pathogen responsible for genital and neonatal infections. Genetically modifying this bacterium is necessary to understand the virulence and infection mechanisms of this pathogen. There is currently no effective molecular tool to engineer the genome of this bacterium, limiting research on its pathogenicity and its peculiar metabolism based on arginine.New technologies have recently emerged in the field of Synthetic Biology (BS), offering new perspectives for the study of mycoplasmas by allowing large scale genome modifications and the production of mutant strains. Work at the J. Craig Venter Institute (JCVI, USA) has shown that the genome of related mycoplasmas can be cloned and manipulated in yeast before being transplanted into a recipient cell. The yeast serves as a temporary host to modify the genome of the bacterium. This innovative approach opens many perspectives in the development of functional genomics in mycoplasmas for which there are few effective genetic tools. The goal of this thesis was to adapt a number of BS tools to M. hominis for the first time, in order to create mutants deficient for a given function. To achieve this goal, the genome of the M. hominis type strain PG21 (665 kb) was cloned into the yeast Saccharomyces cerevisiae by Transformation-Associated Recombination cloning (TAR-cloning). Two yeast clones (B3-2 and B3-4) possessing the complete genome of M. hominis were validated by simplex PCR, multiplex PCR and Pulsed Field Gel Electrophoresis (PFGE) analyses. These yeast clones were then propagated in a selective medium for 180 generations (30 passages) to evaluate the stability of the bacterial genome in its host. This experiment showed that (i) the size of the genome of M. hominis did not change during the first passages, it decreased progressively from the tenth passage (≈60 generations), and (ii) the enriched genome areas in repeated sequence were preferentially lost. Thus, the genome of M. hominis was modified in the B3-4 clone at early passages using the Clustered Regularly Interspaced Short Palindromic Repeats/Cas9 (CRISPR/Cas9) technology. Yeast clones with a complete M. hominis PG21 genome with a deleted vaa gene, encoding a major adhesion protein, were produced using this approach. The final step of this approach was to transplant the modified genome into a recipient cell of M. hominis or Mycoplasma arthritidis, the species phylogenetically closest to M. hominis. As no M. hominis transformation protocol was available at the beginning of our work, this step constituted a major obstacle in the implementation of BS tools in this species. This barrier has been partially lifted since a method of transformation of M. hominis based on polyethylene glycol (PEG) and involving the plasposon pMT85 (plasmid carrying a transposon conferring resistance to tetracycline) has been developed in the laboratory. This transformation technique, developed for the reference strain M. hominis M132 (745 kb) still remains not very efficient; it is nevertheless reproducible and allowed to obtain M. hominis mutants of interest. The Mhom132_2390 gene, encoding the precursor of the P75 protein, a putative adhesin of M. hominis, was effectively mutated in transformant No. 28-2. Complete genome sequencing of other transformants revealed the insertion of multiple copies of the transposon and the presence of duplication and inversion of large DNA fragments within at least two M. hominis genomes.In conclusion, this data has opened the way for the development and transposition of existing genetic modification approaches to M. hominis, previously considered as a genetically intractable bacterium.

A produção de proteínas terapêuticas recombinantes compreende moléculas complexas e de alto valor agregado, incluindo a enzima glucocerebrosidase (GCase). Sua deficiência resulta na Doença de Gaucher, passível de tratamento por meio da terapia de reposição enzimática. A forma ativa da GCase recombinante usada na terapia apresenta resíduos terminais de manose expostos no seu perfil de glicosilação. Perfil este que espera-se ser reproduzido por meio da construção de uma linhagem de Pichia pastoris com um padrão de glicosilação humanizado, por meio da deleção de dois genes envolvidos no sistema de glicosilação da levedura: alg3 e och1, responsáveis pela posterior hiper-manosilação característica desse organismo. Assim, a expressão da GCase será usada como modelo no desenvolvimento desta linhagem de Pichia pastoris que permita a expressão de glicoproteínas com um perfil humanizado específico de glicosilação. Além da produção da linhagem mutante pela técnica de CRISPR/Cas9, propomos a construção de duas linhagens controle: uma expressando a proteína GCase para análise do seu padrão selvagem de glicosilação em P. pastoris e outra expressando a proteína Cas9 de Streptoccocus pyogenes (SpCas9). A linhagem P. pastoris/GCase foi construída testando-se duas sequências sinal de secreção diferentes: fosfatase alcalina (PHO1) e albumina humana (Alb). Resultados de western blot mostraram a GCase no lisado celular e baixos níveis de proteína secretada no sobrenadante de cultura, sendo mais expresso na linhagem contendo a sequência PHO1. A linhagem P. pastoris/SpCas9 foi construída e a enzima SpCas9 foi detectada via western blot no lisado celular após indução com metanol. Para a produção da linhagem com padrão de glicosilação humanizado propôs-se a deleção dos genes alg3 e och1 e a inserção, pela via de reparo por recombinação homóloga (HDR), de marcas de resistência aos antibióticos higromicina ou canamicina. Para tal, propusemos a construção de dois vetores finais de expressão do sistema CRISPR/Cas9 em P. pastoris, cada um contendo a enzima SpCas9 e os RNAs guia (gRNAs) para deleção do gene alg3 ou och1, e também a construção de dois fragmentos para HDR contendo o gene de resistência ao antibiótico flanqueado por regiões de 1Kb de homologia com a região de deleção do gene alg3 ou och1. A construção dos vetores e fragmentos para HDR foram inicialmente feitas por meio de técnicas de clonagem clássica. No entanto, apesar de inúmeras tentativas, resultados de PCR e sequenciamento mostraram o insucesso das construções. Partiu-se então para a técnica de Gibson Assembly®, através da qual os dois fragmentos para HDR foram construídos. Porém, os vetores de expressão contendo SpCas9 e os gRNAs ainda apresentam dificuldades na sua construção. Esforços ainda estão sendo feitos para a construção dos vetores e consequente tentativa de estabelecimento das linhagens mutantes. O sucesso no estabelecimento de um sistema de expressão de proteínas heterólogas com este padrão de glicosilação humano específico permitirá a obtenção e possível comercialização da GCase em sua forma terapêutica. Além disso, permitirá possíveis edições genômicas futuras para um padrão de maior complexidade de glicosilação humanizado, criando uma plataforma nacional para produção de outras glicoproteínas terapêuticas de interesse biotecnológico. / The production of therapeutic recombinant protein comprises complex and high valued molecules, including the glucocerebrosidase enzyme (GCase). Its deficiency results in Gaucher Disease, susceptible of treatment by enzymatic replacement therapy. The active form of recombinant GCase employed in therapy presents exposed terminal mannose residues in its glycosylation pattern. We hope to reproduce such pattern by constructing a Pichia pastoris strain with a specific human glycosylation pattern through the deletion of two genes involved in yeast glycosylation system, alg3 and och1, responsible for the final hyper-mannosylation characteristic of this organism. Therefore, the expression of GCase will be a case model for the development of the recombinant Pichia pastoris strain that could allow the expression of glycoproteins with a specific humanized glycosylation profile. Despite the establishment of the mutant strain using the CRISPR/Cas9 technique, we propose the construction of two control strains: one expressing the GCase protein for analysis of its wild type glycosylation pattern and another one expressing the Cas9 protein from Streptoccocus pyogenes (SpCas9). The P. pastoris/GCase strain was constructed testing two different secretion signal sequences: alkaline fosfatase (PHO1) and human albumin (Alb). Western blot results have shown GCase in cell lysate and in low expression levels in culture supernatant, being more expressed in the strain containing the PHO1 signal sequence. P. pastoris/SpCas9 strain was constructed and SpCas9 enzyme was detected via western blot in cell lysate after the induction with methanol. To produce the strain with the humanized glycosylation pattern, the deletion of alg3 and och1 genes was proposed along with the insertion, by homology directed repair pathway (HDR), of hygromycin and kanamycin antibiotics resistance marks. In order to do so, we have proposed the construction of two final expression vectors of the CRISPR/Cas9 system in P. pastoris, each one containing SpCas9 enzyme and the guide RNAs (gRNAs) for deletion of alg3 or och1, and also the construction of two fragments for HDR containing the antibiotics resistance gene flanked by 1Kb regions of homology with the deleted regions of alg3 or och1. Vectors and HDR fragments constructions were initially performed using classic cloning techniques. However, despite numerous tries, PCR and sequencing results have shown the failure of the constructions. Then, we moved on to the Gibson Assembly® technique, through which the two HDR fragments were built. Still, the expression vectors containing SpCas9 and the gRNAs presented difficulties in its assembly. Efforts continue to be made to successfully construct the remaining vectors and to establish the mutant lineage. Success in the establishment of a heterologous protein expression system with specific human glycosylation pattern will allow the obtainment and possible commercialization of the therapeutic form of GCase. Furthermore, it will also allow possible future genomic editing to a high complexity human glycosylation pattern, creating a national platform for the production of other therapeutic glycoproteins of biotechnological interest.

Les êtres vivants sont confrontés à des parasites qui diminuent leur fitness et se répandent dans la population. En réponse, les hôtes ont développé de nombreuses défenses immunitaires qui sont souvent mises en défaut par l'évolution des parasites. Ces défenses sont de plus souvent extrêmement diversifiées génétiquement. Quel est donc l'apport de la diversité génétique des défenses contre l'évolution des parasites ? Répondre à cette question expérimentalement nécessite un système biologique pour lequel on peut étudier la diversité génétique de l'hôte et l'évolution et la propagation du parasite. Les systèmes bactéries/phages sont de bons candidats pour une telle étude : leur manipulation au laboratoire est aisée, leurs cycles de vie sont rapides et ils ont de forts taux de mutation. La découverte récente de l'immunité CRISPR--Cas a ouvert de nombreuses possibilités : cette dernière a la propriété unique de générer dans le même fond génétique que l'hôte sensible de nombreux allèles de résistance. De plus, son mécanisme de fonctionnement reposant sur une interférence à ARN, la cible d'une résistance est très précisément connue ainsi que les possibilités de la contourner. Ce système permet donc l'étude expérimentale de l'impact de la diversité génétique sur la propagation et l'évolution des parasites, et sur la co-évolution antagoniste. Dans cette thèse, nous cherchons à 1) déterminer l'impact de la composition de la population d'hôtes sur la probabilité qu'une épidémie créée par un virus mutant ait lieu (émergence évolutive), 2) expliciter les causes de l'hétérogénéité de durabilité des résistances et 3) étudier la dynamique co-évolutive entre population génétiquement diversifiée d'hôtes et de parasites. Nous montrons que la composition de la population d'hôtes module fortement la probabilité d'émergence évolutive : une faible diversité génétique associé à un taux intermédiaire d'hôtes sensibles maximisant la probabilité d'émergence évolutive. Dans un second temps, nous montrons que l'immunité CRISPR génère des résistances dont la durabilité est hétérogène et cette hétérogénéité ne peut pas être expliquée par une hétérogénéité des fitness des mutants contournant CRISPR. Enfin, nous montrons que la diversité des résistances est maintenue à court terme par l'hétérogénéité des populations de parasites et que la dynamique co-évolutive est accélérée en présence d'une population génétiquement diverse. Enfin, nous proposons des pistes de recherche qu'il nous parait intéressant d'étudier dans le futur. / Living organisms face parasites which decrease their fitness and spread into their population. In response, hosts have evolved countless immune defenses that are often circumvented by parasite evolution. These defenses are usually extremely diverse. What is the impact of such genetic diversity on the protection against the evolution of parasites? Answering this question experimentally requires an experimental system in which host genetic diversity and parasite evolution and spreading can be monitored. Phages and bacteria systems are ideal candidates for such studies as their handling is easy in the lab, their life cycle is short and their mutation rates is high. The recent discovery of CRISPR--Cas immunity has opened many possibilities. Indeed, this immunity has the unique property to generate in the same genetic background as the sensitive host, numerous resistant alleles. In addition, it relies on an interference--RNA-like pathway, which results in the precise understanding of phage bypassing and in the ability to predict the targeted sequence. This system hence allows the experimental study of the impact of host genetic diversity on the epidemiology and the evolution of parasites and on antagonist coevolution. In this PhD, we 1) study how the host population composition impacts the probability of an epidemic created by an escape mutant (evolutionary emergence), 2) try to understand the causes of the heterogeneity in durability of resistances and 3) monitor the coevolution dynamic between genetically diverse populations. We show that the composition of the host population impacts the probability of evolutionary emergence: a low resistances diversity with an intermediate proportion of sensitive hosts maximises the probability of evolutionary emergence. Second, we show that CRISPR--Cas resistances are heterogeneous in their durability and this is not explained by the heterogeneity of escape mutants fitness. Third, we show that resistances diversity is conserved in a short term by parasites genetic diversity and that the coevolutionary dynamic is fastened by parasite intra-specific genetic diversity. Finally, we discuss research questions that we find interesting to develop in the near future.

L’adrénoleucodystrophie liée à l’X (X-ALD) est une maladie neurodégénérative sévère caractérisée par une accumulation d’acides gras à très longue chaîne (AGTLC), conséquence d’un défaut de β-oxydation peroxysomale. La maladie est associée à l’absence de la protéine ABCD1, transporteur ABC du peroxysome qui, tout comme son homologue le plus proche, ABCD2, participe à l’import des AGTLC-CoA au sein du peroxysome, l’unique site de leur dégradation par β-oxydation. La compréhension des mécanismes physiopathologiques est aujourd’hui limitée par le manque de modèles expérimentaux pertinents, cellulaires ou animaux. Puisque le défaut peroxysomal dans la microglie apparait comme un événement pathogénique majeur, nous avons généré des lignées de cellules microgliales incapable de transporter et/ou β-oxyder les AGTLC au sein du peroxysome. Quatre lignées cellulaires microgliales BV-2 déficientes en ABCD1, ABCD2, ABCD1 et ABCD2 ou ACOX1 (l’enzyme limitante de la β-oxydation peroxysomale) ont ainsi été générées par édition génique par CRISPR-Cas9. Ces cellules déficientes présentent d’importants défauts biochimiques, une accumulation d’AGTLC mais aussi des changements des contenus en acides gras et cholestérol. Les analyses ultrastructurales effectuées démontrent l’existence d’importantes inclusions lipidiques et indiquent également une augmentation du nombre de peroxysomes et mitochondries dans ces cellules. Les profils transcriptomiques signalent des altérations de la plasticité de ces cellules microgliales et de leur capacité de reprogrammation métabolique en réponse à un stimulus inflammatoire. Les fonctions de phagocytose ou de présentation antigénique des cellules microgliales semblent être affectées par le défaut peroxysomal. Enfin, les résultats obtenus à l’aide de ces modèles suggèrent que l’altération du métabolisme lipidique peroxysomal modifie l’organisation des membranes cellulaires. Ces lignées cellulaires apparaissent donc comme des modèles prometteurs, d’un grand intérêt pour la compréhension de la physiopathologie et l’identification de cibles thérapeutiques de cette maladie neurodégénérative complexe. / X-linked adrenoleukodystrophy (X-ALD) is a severe neurodegenerative disorder characterized by very-long-chain fatty acid (VLCFA) accumulation resulting from a peroxisomal β-oxidation defect. The disease is caused by mutations in the ABCD1 gene, which encodes for a peroxisomal half ABC transporter predicted, like its closest homologue ABCD2, to participate in the entry of VLCFA-CoA into the peroxisome, the unique site of their β-oxidation. Progress in understanding the physiopathogenesis of X-ALD suffers from the lack of appropriate cell and animal models. Since peroxisomal defects in microglia seem to be a key element of the onset of the disease, we generated four microglial cell lines unable to transport and/or β-oxidize VLCFA into the peroxisome. BV-2 microglial cells were engineered with CRISPR-Cas9 to generate four microglial cell lines deficient in ABCD1, ABCD2, both ABCD1 and ABCD2 or ACOX-1 (the first rate-limiting enzyme of the peroxisomal β-oxidation system). Biochemical defects and lipid content changes associated with VLCFA accumulation but also fatty acids and cholesterol changes were identified in deficient microglia. Ultrastructural investigations confirmed cytosolic lipid inclusions and an increased number of peroxisome and mitochondria. Transcriptomic profiles of deficient microglia are indicative of an impaired plasticity and an impaired capacity to operate the metabolic shift required upon an inflammatory stimulation. Peroxisomal defect is likely to affect phagocytosis and antigen presentation capacity of microglia. Peroxisomal lipid metabolism defect is also suggested to modify cell membranes organization. Altogether, these novel mutant cell lines represent a promising model that should permit identification of new therapeutic targets for this complex neurodegenerative disease.